CHANG JOSEPH Y
Known title: EVP, Chief Scientific OfficerCIK: 0001184201
Associated companies
Transaction History
| NUS | ▲ Buy | Option Exercise | 600 | $18K | 3/2/2023 | View on chart |
| NUS | ▲ Buy | Option Exercise | 24,400 | $743K | 3/2/2023 | View on chart |
| NUS | ▼ Sell | Open Market | 25,000 | $1.0M | 3/2/2023 | View on chart |
| NUS | ▲ Buy | Option Exercise | 68,485 | $2.1M | 3/1/2023 | View on chart |
| NUS | ▼ Sell | Open Market | 68,485 | $2.8M | 3/1/2023 | View on chart |
| NUS | ▼ Sell | Tax Withholding | 1,981 | $90K | 2/15/2023 | View on chart |
| NUS | ▲ Buy | Option Exercise | 6,800 | $256K | 12/18/2022 | View on chart |
| NUS | ▼ Sell | Tax Withholding | 6,542 | $264K | 12/18/2022 | View on chart |
| NUS | ▲ Buy | Option Exercise | 16,000 | $490K | 6/1/2022 | View on chart |
| NUS | ▼ Sell | Open Market | 8,975 | $415K | 6/1/2022 | View on chart |
| NUS | ▼ Sell | Open Market | 7,025 | $330K | 6/1/2022 | View on chart |
| NUS | ▼ Sell | Open Market | 2,500 | $115K | 3/2/2022 | View on chart |
| NUS | ▲ Buy | Option Exercise | 3,423 | $105K | 3/2/2022 | View on chart |
| NUS | ▼ Sell | Open Market | 923 | $43K | 3/2/2022 | View on chart |
| NUS | ▲ Buy | Option Exercise | 28,577 | $875K | 3/1/2022 | View on chart |
| NUS | ▼ Sell | Open Market | 28,280 | $1.3M | 3/1/2022 | View on chart |
| NUS | ▼ Sell | Open Market | 297 | $14K | 3/1/2022 | View on chart |
| NUS | ▲ Buy | Grant | 6,744 | $0 | 2/25/2022 | View on chart |
| NUS | ▼ Sell | Tax Withholding | 1,729 | $86K | 2/15/2022 | View on chart |
| NUS | ▲ Buy | Option Exercise | 16,000 | $490K | 9/13/2021 | View on chart |
| NUS | ▼ Sell | Open Market | 16,000 | $759K | 9/13/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Nu Skin: Turnaround Narrative Gains Attention
A recent analysis suggests that Nu Skin's potential turnaround may be in its early stages. The company currently trades at a low price with a high dividend yield, while the stock is testing a key support level. This context highlights the contrast between current market sentiment and the long-term outlook discussed in the news.
Nu Skin: Turnaround Narrative Gains Attention. A recent analysis suggests that Nu Skin's potential turnaround may be in its early stages. The company currently trades at a low price with a high dividend yield, while the stock is testing a key support level. This context highlights the contrast between current market sentiment and the long-term outlook discussed in the news.